PPARA and polycystic kidney disease: Furthermore, treatment with the peroxisome proliferator-activated receptor-α (PPAR-α) agonist could reduce the pathology of polycystic kidney disease (PKD) and potentially improve the renal function of the disease by modulating mitophagy [136].